Gossamer Bio

Gossamer Bio is a California-based biopharmaceutical company that develops and commercializes novel therapies for the treatment of cancer and inflammatory diseases.

Business Model:

Revenue: $0

Employees: 51-200

Detailed Gossamer Bio Information

Geographic Data

Gossamer Bio headquarters map

Address: 3013 Science Park Road

City: San Diego

State: CA

Zip: 92121

Country: US

Financial Info

Stage:

post ipo equity

Raised Last:

$120M

Raised Total:

$600M

Metrics

2,598,809Website Global Rank

6,824Website Monthly Traffic

Twitter Followers

Description

Gossamer Bio is a California-based biopharmaceutical company that develops and commercializes novel therapies for the treatment of cancer and inflammatory diseases.

Contact Phone:
+18589220718

Contact Email:

Gossamer Bio went public on 2/8/2019 on the NASDAQ

Listed Exchange:
NASDAQ

IPO Date:
2/8/2019

IPO Valuation:
$1B

Ticker Symbol:
GOSS

IPO Price:
$16/share

Amount Raised:
$276M

Live

Opened: -/share

EBITDA -
Total Cash -
Total Debt -
Total Revenue -
Total Profit (Gross) -
PE Ratio -
Announced Date Company Transaction Money Raised
Announced Date Transaction Number of Investors Money Raised Lead Investors
7/2022 Post-IPO Equity $0 Boxer Capital
EcoR1 Capital
Invus
Madison Avenue Partners
Monashee Investment Management
New Enterprise Associates
Rock Springs Capital
Weiss Asset Management
Boxer Capital
EcoR1 Capital
Invus
Madison Avenue Partners
Monashee Investment Management
New Enterprise Associates
Rock Springs Capital
Weiss Asset Management
1/2018 Series A 2 $100M ARCH Venture Partners
Omega Funds
ARCH Venture Partners
Omega Funds
7/2018 Series B $0 Bay City Capital
Hillhouse Capital Group
Abu Dhabi Investment Authority
ARCH Venture Partners
Invus
Omega Funds
Polaris Partners
The Baupost Group
Bay City Capital
Hillhouse Capital Group
Abu Dhabi Investment Authority
ARCH Venture Partners
Invus
Omega Funds
Polaris Partners
The Baupost Group
5/2019 Post-IPO Debt 1 $150M MidCap Financial
MidCap Financial
MidCap Financial
MidCap Financial
2/2019 IPO $264.5M
5/2019 Post-IPO Debt -
7/2022 Private Placement $120M EcoR1 Capital
New Enterprise Associates
Weiss Asset Management
Madison Avenue Partners
Rock Springs Capital
Boxer Capital
Invus
Monashee Investment Management
7/2018 Series B $230M Hillhouse Capital Management, Ltd.
The Baupost Group
Polaris Partners
ARCH Venture Partners
Omega Funds
5/2019 Post-IPO Debt - MidCap Financial
MidCap Financial
7/2022 Post-IPO Equity 8 $120M Boxer Capital
EcoR1 Capital
Invus
Madison Avenue Partners
Monashee Investment Management
New Enterprise Associates
Rock Springs Capital
Weiss Asset Management
Boxer Capital
EcoR1 Capital
Invus
Madison Avenue Partners
Monashee Investment Management
New Enterprise Associates
Rock Springs Capital
Weiss Asset Management
7/2018 Series B 8 $230M Bay City Capital
Hillhouse Capital Group
Bay City Capital
Hillhouse Capital Group
Announced Date Name Price
7/2019 Adhaere Pharmaceuticals

Employee Departments

Employee States

Uniview Singapore VEID Logo
Uniview Singapore VEID
Revenue: 0 - 100000
Employees:
Industry: Software
Details
Konkuk University Medical Center Logo
Konkuk University Medical Center
Revenue: 0 - 100000
Employees: 51 - 500
Industry: Education
Details
Daemon Technologies Logo
Daemon Technologies
Revenue: 0 - 100000
Employees: 1 - 10
Industry: Blockchain
Details
Ace International Trade Logo
Ace International Trade
Revenue: 0 - 100000
Employees: 11 - 50
Industry: Industrial
Details
An Hòa Communications Logo
An Hòa Communications
Revenue: 0 - 100000
Employees: 1 - 10
Industry: Advertising
Details

You know, we could be doing all this for you..

CoBee's Logo

Be ahead of your competition

  • Realtime intelligence
  • Automated contact tracking
  • Unmatched insights
  • Eliminate manual research